These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20171385)

  • 1. Chemo-immunotherapy in RCC: the end of a story.
    Escudier B
    Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385
    [No Abstract]   [Full Text] [Related]  

  • 2. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
    Porta C
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
    Amato R
    Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
    Huland E; Heinzer H
    Br J Cancer; 2000 Jan; 82(1):246-7. PubMed ID: 10638997
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
    Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in metastatic renal cell carcinoma.
    Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
    World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for renal cell carcinoma.
    Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
    Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Of snails and holy grails..
    Yang JC
    Cancer J Sci Am; 1997; 3(3):142-3. PubMed ID: 9161778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.